If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.
Slafsky believes if one or both chambers flip, the 340B program will “get a very close look” by lawmakers. He notes that Republican members of the House Energy & Commerce Committee recently tried but failed to introduce a host of amendments considered extremely burdensome by 340B providers to the Democrats’ drug pricing bill. The bill is part of the huge budget reconciliation package currently being debated in the House.
If Congress changes hands during next year’s mid-term elections, we can expect the 340B program to be back under the spotlight with a renewed effort to place significant restrictions on the program, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
